Our data suggest that iDGAT treatment affects myeloid cells to hamper the infiltration of CD8 T cells into the tumor SCD1 inhibitor CAY10566 did not affect the tumor growth, which may be due to the compensation of extracellular fatty acids. The gene discussed is CD8A; the disease is neoplasm.